questionsmedicales.fr
Facteurs biologiques
Protéines et peptides de signalisation intercellulaire
Protéines de la superfamille du TGF bêta
Protéines de la superfamille du TGF bêta : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Protéines de la superfamille du TGF bêta : Questions médicales les plus fréquentes",
"headline": "Protéines de la superfamille du TGF bêta : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Protéines de la superfamille du TGF bêta : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-20",
"dateModified": "2025-04-16",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Protéines de la superfamille du TGF bêta"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Protéines et peptides de signalisation intercellulaire",
"url": "https://questionsmedicales.fr/mesh/D036341",
"about": {
"@type": "MedicalCondition",
"name": "Protéines et peptides de signalisation intercellulaire",
"code": {
"@type": "MedicalCode",
"code": "D036341",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Protéines morphogénétiques osseuses",
"alternateName": "Bone Morphogenetic Proteins",
"url": "https://questionsmedicales.fr/mesh/D019485",
"about": {
"@type": "MedicalCondition",
"name": "Protéines morphogénétiques osseuses",
"code": {
"@type": "MedicalCode",
"code": "D019485",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.200"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Protéine morphogénétique osseuse de type 2",
"alternateName": "Bone Morphogenetic Protein 2",
"url": "https://questionsmedicales.fr/mesh/D055396",
"about": {
"@type": "MedicalCondition",
"name": "Protéine morphogénétique osseuse de type 2",
"code": {
"@type": "MedicalCode",
"code": "D055396",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.200.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protéine morphogénétique osseuse de type 3",
"alternateName": "Bone Morphogenetic Protein 3",
"url": "https://questionsmedicales.fr/mesh/D055398",
"about": {
"@type": "MedicalCondition",
"name": "Protéine morphogénétique osseuse de type 3",
"code": {
"@type": "MedicalCode",
"code": "D055398",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.200.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protéine morphogénétique osseuse de type 4",
"alternateName": "Bone Morphogenetic Protein 4",
"url": "https://questionsmedicales.fr/mesh/D055415",
"about": {
"@type": "MedicalCondition",
"name": "Protéine morphogénétique osseuse de type 4",
"code": {
"@type": "MedicalCode",
"code": "D055415",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.200.400"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protéine morphogénétique osseuse de type 5",
"alternateName": "Bone Morphogenetic Protein 5",
"url": "https://questionsmedicales.fr/mesh/D055417",
"about": {
"@type": "MedicalCondition",
"name": "Protéine morphogénétique osseuse de type 5",
"code": {
"@type": "MedicalCode",
"code": "D055417",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.200.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protéine morphogénétique osseuse de type 6",
"alternateName": "Bone Morphogenetic Protein 6",
"url": "https://questionsmedicales.fr/mesh/D055418",
"about": {
"@type": "MedicalCondition",
"name": "Protéine morphogénétique osseuse de type 6",
"code": {
"@type": "MedicalCode",
"code": "D055418",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.200.600"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protéine morphogénétique osseuse de type 7",
"alternateName": "Bone Morphogenetic Protein 7",
"url": "https://questionsmedicales.fr/mesh/D055419",
"about": {
"@type": "MedicalCondition",
"name": "Protéine morphogénétique osseuse de type 7",
"code": {
"@type": "MedicalCode",
"code": "D055419",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.200.700"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de croissance et de différenciation",
"alternateName": "Growth Differentiation Factors",
"url": "https://questionsmedicales.fr/mesh/D055412",
"about": {
"@type": "MedicalCondition",
"name": "Facteurs de croissance et de différenciation",
"code": {
"@type": "MedicalCode",
"code": "D055412",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.300"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Protéine morphogénétique osseuse de type 15",
"alternateName": "Bone Morphogenetic Protein 15",
"url": "https://questionsmedicales.fr/mesh/D055430",
"about": {
"@type": "MedicalCondition",
"name": "Protéine morphogénétique osseuse de type 15",
"code": {
"@type": "MedicalCode",
"code": "D055430",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.300.049"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur-2 de croissance et de différenciation",
"alternateName": "Growth Differentiation Factor 2",
"url": "https://questionsmedicales.fr/mesh/D055427",
"about": {
"@type": "MedicalCondition",
"name": "Facteur-2 de croissance et de différenciation",
"code": {
"@type": "MedicalCode",
"code": "D055427",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.300.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur-5 de croissance et de différenciation",
"alternateName": "Growth Differentiation Factor 5",
"url": "https://questionsmedicales.fr/mesh/D055428",
"about": {
"@type": "MedicalCondition",
"name": "Facteur-5 de croissance et de différenciation",
"code": {
"@type": "MedicalCode",
"code": "D055428",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.300.500"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur-6 de croissance et de différenciation",
"alternateName": "Growth Differentiation Factor 6",
"url": "https://questionsmedicales.fr/mesh/D055431",
"about": {
"@type": "MedicalCondition",
"name": "Facteur-6 de croissance et de différenciation",
"code": {
"@type": "MedicalCode",
"code": "D055431",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.300.600"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur-9 de croissance et de différenciation",
"alternateName": "Growth Differentiation Factor 9",
"url": "https://questionsmedicales.fr/mesh/D055429",
"about": {
"@type": "MedicalCondition",
"name": "Facteur-9 de croissance et de différenciation",
"code": {
"@type": "MedicalCode",
"code": "D055429",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.300.800"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur-10 de croissance et de différenciation",
"alternateName": "Growth Differentiation Factor 10",
"url": "https://questionsmedicales.fr/mesh/D055413",
"about": {
"@type": "MedicalCondition",
"name": "Facteur-10 de croissance et de différenciation",
"code": {
"@type": "MedicalCode",
"code": "D055413",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.300.900"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur-15 de croissance et de différenciation",
"alternateName": "Growth Differentiation Factor 15",
"url": "https://questionsmedicales.fr/mesh/D055436",
"about": {
"@type": "MedicalCondition",
"name": "Facteur-15 de croissance et de différenciation",
"code": {
"@type": "MedicalCode",
"code": "D055436",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.300.915"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Myostatine",
"alternateName": "Myostatin",
"url": "https://questionsmedicales.fr/mesh/D055435",
"about": {
"@type": "MedicalCondition",
"name": "Myostatine",
"code": {
"@type": "MedicalCode",
"code": "D055435",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.300.925"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Ligands de la voie de signalisation Nodal",
"alternateName": "Nodal Signaling Ligands",
"url": "https://questionsmedicales.fr/mesh/D055456",
"about": {
"@type": "MedicalCondition",
"name": "Ligands de la voie de signalisation Nodal",
"code": {
"@type": "MedicalCode",
"code": "D055456",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.550"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Facteur-1 de croissance et de différenciation",
"alternateName": "Growth Differentiation Factor 1",
"url": "https://questionsmedicales.fr/mesh/D055452",
"about": {
"@type": "MedicalCondition",
"name": "Facteur-1 de croissance et de différenciation",
"code": {
"@type": "MedicalCode",
"code": "D055452",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.550.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur-3 de croissance et de différenciation",
"alternateName": "Growth Differentiation Factor 3",
"url": "https://questionsmedicales.fr/mesh/D055451",
"about": {
"@type": "MedicalCondition",
"name": "Facteur-3 de croissance et de différenciation",
"code": {
"@type": "MedicalCode",
"code": "D055451",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.550.300"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de détermination de l'asymétrie droite-gauche",
"alternateName": "Left-Right Determination Factors",
"url": "https://questionsmedicales.fr/mesh/D055458",
"about": {
"@type": "MedicalCondition",
"name": "Facteurs de détermination de l'asymétrie droite-gauche",
"code": {
"@type": "MedicalCode",
"code": "D055458",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.550.475"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Protéine Nodal",
"alternateName": "Nodal Protein",
"url": "https://questionsmedicales.fr/mesh/D055457",
"about": {
"@type": "MedicalCondition",
"name": "Protéine Nodal",
"code": {
"@type": "MedicalCode",
"code": "D055457",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.550.650"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Facteur de croissance transformant bêta",
"alternateName": "Transforming Growth Factor beta",
"url": "https://questionsmedicales.fr/mesh/D016212",
"about": {
"@type": "MedicalCondition",
"name": "Facteur de croissance transformant bêta",
"code": {
"@type": "MedicalCode",
"code": "D016212",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.775"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Facteur de croissance transformant bêta-1",
"alternateName": "Transforming Growth Factor beta1",
"url": "https://questionsmedicales.fr/mesh/D053773",
"about": {
"@type": "MedicalCondition",
"name": "Facteur de croissance transformant bêta-1",
"code": {
"@type": "MedicalCode",
"code": "D053773",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.775.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur de croissance transformant bêta-2",
"alternateName": "Transforming Growth Factor beta2",
"url": "https://questionsmedicales.fr/mesh/D053781",
"about": {
"@type": "MedicalCondition",
"name": "Facteur de croissance transformant bêta-2",
"code": {
"@type": "MedicalCode",
"code": "D053781",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.775.200"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Facteur de croissance transformant bêta-3",
"alternateName": "Transforming Growth Factor beta3",
"url": "https://questionsmedicales.fr/mesh/D053782",
"about": {
"@type": "MedicalCondition",
"name": "Facteur de croissance transformant bêta-3",
"code": {
"@type": "MedicalCode",
"code": "D053782",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.529.942.775.300"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Protéines de la superfamille du TGF bêta",
"alternateName": "TGF-beta Superfamily Proteins",
"code": {
"@type": "MedicalCode",
"code": "D055411",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Hong-Lian Wang",
"url": "https://questionsmedicales.fr/author/Hong-Lian%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Research Center for Integrative Medicine, The Affiliated Traditional Medicine Hospital of Southwest Medical University, Luzhou 646000, China."
}
},
{
"@type": "Person",
"name": "Li Wang",
"url": "https://questionsmedicales.fr/author/Li%20Wang",
"affiliation": {
"@type": "Organization",
"name": "Research Center for Integrative Medicine, The Affiliated Traditional Medicine Hospital of Southwest Medical University, Luzhou 646000, China."
}
},
{
"@type": "Person",
"name": "Hui-Yao Lan",
"url": "https://questionsmedicales.fr/author/Hui-Yao%20Lan",
"affiliation": {
"@type": "Organization",
"name": "Department of Medicine and Therapeutics, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong 999077, China."
}
},
{
"@type": "Person",
"name": "Penny J Beuning",
"url": "https://questionsmedicales.fr/author/Penny%20J%20Beuning",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States."
}
},
{
"@type": "Person",
"name": "Mary Jo Ondrechen",
"url": "https://questionsmedicales.fr/author/Mary%20Jo%20Ondrechen",
"affiliation": {
"@type": "Organization",
"name": "Department of Chemistry and Chemical Biology, Northeastern University, Boston, Massachusetts 02115, United States."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "The association of IL-33 and systemic sclerosis: a systematic review and meta-analysis.",
"datePublished": "2022-10-28",
"url": "https://questionsmedicales.fr/article/36306005",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12026-022-09329-1"
}
},
{
"@type": "ScholarlyArticle",
"name": "Spectrum of renal disease in scleroderma other than scleroderma renal crisis: A review of the literature.",
"datePublished": "2024-05-03",
"url": "https://questionsmedicales.fr/article/38699985",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.5414/CN111243"
}
},
{
"@type": "ScholarlyArticle",
"name": "Myositis mimics in scleroderma: A case series of neuromuscular diseases that can co-exist in scleroderma.",
"datePublished": "2023-09-18",
"url": "https://questionsmedicales.fr/article/38333529",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/23971983231197442"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of pregnancy on scleroderma progression.",
"datePublished": "2022-06-19",
"url": "https://questionsmedicales.fr/article/36743807",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1177/23971983221101311"
}
},
{
"@type": "ScholarlyArticle",
"name": "Reference value for the 6-min walking distance in women with systemic sclerosis considering the impact of muscle strength.",
"datePublished": "2023-09-15",
"url": "https://questionsmedicales.fr/article/37725867",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.clinbiomech.2023.106094"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines et peptides de signalisation intercellulaire",
"item": "https://questionsmedicales.fr/mesh/D036341"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines de la superfamille du TGF bêta",
"item": "https://questionsmedicales.fr/mesh/D055411"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Protéines de la superfamille du TGF bêta - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Protéines de la superfamille du TGF bêta",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Protéines de la superfamille du TGF bêta",
"description": "Comment diagnostiquer une dysfonction des protéines TGF bêta ?\nQuels tests sont utilisés pour évaluer les niveaux de TGF bêta ?\nLes imageries sont-elles utiles pour le diagnostic ?\nQuels symptômes peuvent indiquer un problème avec TGF bêta ?\nY a-t-il des biomarqueurs associés aux protéines TGF bêta ?",
"url": "https://questionsmedicales.fr/mesh/D055411?mesh_terms=Scleroderma,+Diffuse&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Protéines de la superfamille du TGF bêta",
"description": "Quels sont les symptômes d'une surproduction de TGF bêta ?\nComment la déficience en TGF bêta se manifeste-t-elle ?\nLes symptômes varient-ils selon le type de TGF bêta ?\nY a-t-il des symptômes associés à des cancers liés à TGF bêta ?\nLes symptômes sont-ils similaires chez tous les patients ?",
"url": "https://questionsmedicales.fr/mesh/D055411?mesh_terms=Scleroderma,+Diffuse&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Protéines de la superfamille du TGF bêta",
"description": "Peut-on prévenir les troubles liés à TGF bêta ?\nY a-t-il des facteurs environnementaux à surveiller ?\nLes examens réguliers peuvent-ils aider à la prévention ?\nL'exercice physique a-t-il un impact sur TGF bêta ?\nLes habitudes alimentaires influencent-elles TGF bêta ?",
"url": "https://questionsmedicales.fr/mesh/D055411?mesh_terms=Scleroderma,+Diffuse&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Protéines de la superfamille du TGF bêta",
"description": "Quels traitements ciblent les protéines TGF bêta ?\nLes inhibiteurs de TGF bêta sont-ils efficaces ?\nY a-t-il des traitements naturels pour réguler TGF bêta ?\nComment la thérapie génique peut-elle aider ?\nLes traitements sont-ils personnalisés selon le patient ?",
"url": "https://questionsmedicales.fr/mesh/D055411?mesh_terms=Scleroderma,+Diffuse&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Protéines de la superfamille du TGF bêta",
"description": "Quelles complications peuvent survenir avec TGF bêta ?\nLes complications sont-elles réversibles ?\nComment les complications affectent-elles la qualité de vie ?\nY a-t-il des complications spécifiques aux cancers liés à TGF bêta ?\nLes complications sont-elles prévisibles ?",
"url": "https://questionsmedicales.fr/mesh/D055411?mesh_terms=Scleroderma,+Diffuse&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Protéines de la superfamille du TGF bêta",
"description": "Quels sont les principaux facteurs de risque liés à TGF bêta ?\nL'obésité est-elle un facteur de risque pour TGF bêta ?\nLe tabagisme influence-t-il TGF bêta ?\nY a-t-il des facteurs génétiques associés à TGF bêta ?\nLe stress peut-il affecter TGF bêta ?",
"url": "https://questionsmedicales.fr/mesh/D055411?mesh_terms=Scleroderma,+Diffuse&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des protéines TGF bêta ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le diagnostic repose sur des tests sanguins et des analyses génétiques pour détecter des anomalies."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les niveaux de TGF bêta ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des dosages ELISA et des tests immunologiques sont couramment utilisés pour mesurer les niveaux."
}
},
{
"@type": "Question",
"name": "Les imageries sont-elles utiles pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les imageries peuvent aider à évaluer les effets des anomalies TGF bêta sur les tissus."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec TGF bêta ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme l'inflammation chronique ou des troubles de la cicatrisation peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des biomarqueurs associés aux protéines TGF bêta ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des biomarqueurs comme le TGF-β1 sont souvent utilisés pour évaluer l'activité de la protéine."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une surproduction de TGF bêta ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surproduction peut entraîner fibrose, inflammation et troubles immunitaires."
}
},
{
"@type": "Question",
"name": "Comment la déficience en TGF bêta se manifeste-t-elle ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se manifester par des troubles de la cicatrisation et des maladies auto-immunes."
}
},
{
"@type": "Question",
"name": "Les symptômes varient-ils selon le type de TGF bêta ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, différents isoformes de TGF bêta peuvent provoquer des symptômes variés."
}
},
{
"@type": "Question",
"name": "Y a-t-il des symptômes associés à des cancers liés à TGF bêta ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des cancers peuvent présenter des symptômes comme la douleur, la fatigue et la perte de poids."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils similaires chez tous les patients ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, les symptômes peuvent varier considérablement d'un patient à l'autre."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés à TGF bêta ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines mesures de style de vie, comme une alimentation saine, peuvent aider à prévenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs environnementaux à surveiller ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à des toxines et à des polluants peut influencer l'activité de TGF bêta."
}
},
{
"@type": "Question",
"name": "Les examens réguliers peuvent-ils aider à la prévention ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers peuvent détecter précocement des anomalies liées à TGF bêta."
}
},
{
"@type": "Question",
"name": "L'exercice physique a-t-il un impact sur TGF bêta ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut moduler l'expression des protéines TGF bêta."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles TGF bêta ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en antioxydants peut aider à réguler l'activité de TGF bêta."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent les protéines TGF bêta ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des thérapies ciblées et des anticorps monoclonaux sont en développement pour inhiber TGF bêta."
}
},
{
"@type": "Question",
"name": "Les inhibiteurs de TGF bêta sont-ils efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils montrent des résultats prometteurs dans le traitement de certaines maladies fibrosantes."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements naturels pour réguler TGF bêta ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines plantes médicinales et nutriments peuvent moduler l'activité de TGF bêta."
}
},
{
"@type": "Question",
"name": "Comment la thérapie génique peut-elle aider ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "La thérapie génique pourrait corriger les anomalies génétiques affectant TGF bêta."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés selon le patient ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des besoins spécifiques du patient."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec TGF bêta ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent la fibrose, des maladies auto-immunes et des cancers."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié."
}
},
{
"@type": "Question",
"name": "Comment les complications affectent-elles la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles peuvent réduire la qualité de vie en provoquant douleur et limitations fonctionnelles."
}
},
{
"@type": "Question",
"name": "Y a-t-il des complications spécifiques aux cancers liés à TGF bêta ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des complications comme la métastase et la résistance au traitement peuvent survenir."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles prévisibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être prévisibles en fonction des antécédents médicaux."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque liés à TGF bêta ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents familiaux, des maladies inflammatoires et l'âge."
}
},
{
"@type": "Question",
"name": "L'obésité est-elle un facteur de risque pour TGF bêta ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'obésité peut augmenter l'expression des protéines TGF bêta et aggraver les maladies."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il TGF bêta ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme peut altérer l'activité de TGF bêta et contribuer à des maladies respiratoires."
}
},
{
"@type": "Question",
"name": "Y a-t-il des facteurs génétiques associés à TGF bêta ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines mutations génétiques peuvent affecter la régulation de TGF bêta."
}
},
{
"@type": "Question",
"name": "Le stress peut-il affecter TGF bêta ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut influencer l'expression des protéines TGF bêta."
}
}
]
}
]
}
A meta-analysis of the association between IL-33 and these diseases is lacking, and we aimed to perform a meta-analysis of the association between IL-33 and systemic sclerosis (SSc). We searched relev...
Systemic sclerosis (SSc) is a multi-system rheumatic disease characterized by vascular and fibrotic manifestations that can affect practically every organ. Scleroderma renal crisis (SRC) is the most c...
A literature search was conducted on PubMed and Cochrane from inception to December 2022 using medical subject headings (MeSH) terms for "scleroderma", "systemic sclerosis" combined with "renal injury...
The initial search revealed 393 articles. After the exclusion of duplicates and non-relevant articles, data was included from 30 articles and 45 patients. The mean age was 55.2 years, 9 males (20%) an...
The spectrum of kidney involvement in SSc can range from asymptomatic reduction of the glomerular filtration rate to life-threatening scleroderma renal crisis. Therefore, it is essential that physicia...
We present a case series of four patients with systemic sclerosis and skeletal myopathy. While idiopathic inflammatory myopathies, or myositis, are thought to be the most common type of muscle disease...
To explore the trajectory of scleroderma disease activity in women who experienced a pregnancy after systemic sclerosis diagnosis compared to nulliparous women....
We analyzed data from the Canadian Scleroderma Research Group registry by identifying nulliparous women and women with ⩾1 pregnancy after systemic sclerosis diagnosis. Patient characteristics were com...
At registry entry, numbers of women in the nulliparous and pregnancy after systemic sclerosis diagnosis groups were 153 and 45, respectively. Corresponding numbers at 6 and 9 years were 48 and 21, and...
Results demonstrated that having ⩾1 pregnancy after systemic sclerosis diagnosis did not appear to significantly impact long-term renal, respiratory, or global function outcomes. While this offers a h...
Early triage, the search for new therapies, and closer monitoring of patients with systemic sclerosis before their lung function irreversibly deteriorates are urgent concerns. Because it is an indepen...
This was a cross-sectional study in which 69 women with systemic sclerosis underwent the 6-min walk test, Health Assessment Questionnaire-Disability Index, pulmonary function, handgrip strength test, ...
The mean 6-min walking distance was 447 ± 78 m, and 43.5% of the participants did not reach 80% of their predicted value. 6-min walking distance correlated positively with quadriceps strength (r = 0.4...
Muscle function and, to a lesser extent, lung function are key contributors in determining the reference value for the 6-min walking distance in women with diffuse cutaneous systemic sclerosis-associa...
Coexistence of the skin manifestations of systemic sclerosis and psoriasis is rare. The link between systemic sclerosis and psoriasis has been poorly investigated. We report a case of a 70-year-old wo...
Current recommendations on the management of systemic sclerosis (SSc) suggest that autologous hematopoietic stem cell therapy (HSCT) can be a rescue therapy for patients with rapidly progressive SSc....
To assess the safety and efficacy of HSCT for patients with SSc and to compare these with non-HSCT patients in a control cohort with adjusted risk factors....
A retrospective analysis of data from the multicentric German network for systemic scleroderma (DNSS) with 5000 patients with SSc. Control groups consisted of all patients with diffuse cutaneous (dc)-...
Eighty SSc patients received an HSCT 4.1 ± 4.8 years after SSc diagnosis. Among them, 86.3% had dc-SSc, 43.5% were males, and 71.3% were positive for Scl70 antibodies. The control group A (n=1513) sho...
Our analysis of real-life data show that the distribution of risk factors for mortality is critical when HSCT cohorts are compared with non-HSCT control groups....
Many indigenous non-Caucasian populations, including Native Americans, have been reported to have higher rates, distinct clinical phenotypes, increased complications, and greater severity of systemic ...
This cross-sectional retrospective study included 137 SSc patients (109 [80%] were non-Native and 28 [20%] were Native Americans) followed over a mean of 11.5 ± 7.6 years. Participants were repetitive...
The estimated prevalence of SSc in Native Americans was 40.0 cases/100 000 vs 17.1 cases/100 000 for non-Natives (odds ratio 2.34, 95% confidence interval [CI] 1.55-3.55, P < .001). The cohorts were s...
In Native Americans of the American Southwest, SSc is increased in prevalence but is phenotypically similar to SSc in non-Natives. However, mortality due specifically to infection is increased in Nati...
Overlap syndrome (OS) is a group of systemic connective tissue diseases (CTDs) that meet the criteria of two or more CTDs. In this study, we evaluated clinical, laboratory, and capillaroscopic manifes...
In a 10-year cross-sectional study, we evaluated 135 adult patients (70 with SSc-OS and 65 with LcSSc) with the same skin score for their baseline and follow-up clinical, laboratory, high-resolution c...
Of the 135 patients, 70 had SSc-OS, including 45 (64.3%) cases of SSc-SS (Sjögren's syndrome), 11 (15.7%) of SSc-RA (rheumatoid arthritis), 9 (12.9%) of SSc-myositis and 5 (1.7%) of SSc-SLE (systemic ...
In SSc-OS patients, the most common subgroup was SSc-SS. Scleroderma OS was associated with lower major organ involvement and capillaroscopy progression than LcSSc. Major organ involvement in patients...
Juvenile localized scleroderma (jLS) is a chronic autoimmune disease commonly associated with poor outcome, including contractures, hemi-atrophy, uveitis, and seizures. Despite improvements in treatme...
LoTSS was developed as a weighted measure by a consensus process involving literature review, surveys, case vignettes, and multi-criteria decision analysis. Feasibility was assessed in larger Childhoo...
LoTSS severity items were organized into modules that reflect jLS disease patterns, with modules for skin, extracutaneous, and craniofacial manifestations. Construct validity of LoTSS was supported by...
We developed a new LS measure for assessing cutaneous and extracutaneous severity, and have shown it to be reliable, valid, and responsive. LoTSS is the first measure that assesses and scores all the ...